Vecoy Nanomedicines

Company Overview

Snapshot

Founded in October 2010 by Erez Livneh, Vecoy Nanomedicines operates with 1–10 employees. The company has raised $2 million across one funding round. In November 2013, the company secured a grant, indicating early validation for its innovative technology.

Business overview

Vecoy Nanomedicines specializes in developing novel nano-scale virus traps designed to capture and destroy viruses. Its core technology involves patent-pending virus decoys that mimic human host cells, targeting viruses before cellular infection occurs. This approach aims to address challenges in existing antiviral treatments, such as virus resistance and toxicity. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Drug Delivery, with a market presence in the United States.

Strategic signal

In June 2016, Vecoy Nanomedicines secured a patent for its pathogen and substance traps. This patent highlights the company's commitment to protecting its innovative nanotechnology, which uses virus decoys to combat viral diseases. For investors, this signals a validation of the company's unique scientific approach and its potential for long-term impact in the antiviral therapy market, despite its current non-active status.

Company Intelligence Q&A

What is Vecoy Nanomedicines' core technology?

Vecoy Nanomedicines develops nano-scale virus traps that mimic human host cells to capture and destroy viruses, targeting them before they can infect cells. This technology is designed to overcome issues of virus resistance and toxicity associated with current antiviral treatments.

When was Vecoy Nanomedicines founded?

Vecoy Nanomedicines was founded in October 2010 by Erez Livneh.

What was a significant intellectual property milestone for Vecoy Nanomedicines?

In June 2016, Vecoy Nanomedicines had its patent for 'PATHOGEN AND SUBSTANCE TRAPS' published, highlighting its innovative approach to antiviral therapy.

What is the company's operational status?

Vecoy Nanomedicines is currently non-active, having ceased operations in October 2018.

What was a notable early recognition for Vecoy Nanomedicines?

In December 2013, Vecoy Nanomedicines received an 'outer-space research prize' for its virus-killer technology, as reported by israel21c.org.